Latest Breaking News On - Melissal johnson - Page 1 : vimarsana.com

Dr Johnson on the Efficacy of RMC-6236 in KRAS-Mutant NSCLC

Melissa L. Johnson, MD, discusses the preliminary efficacy findings from the phase 1 RMC-6236-001 trial in patients with non–small cell lung cancer harboring KRAS mutations and details the significance of these findings for patients within the KRAS G12X-mutant NSCLC population.

Melissal johnsonSarah cannon research instituteRmc 6236 001 trialPatients with non small cell lung cancerKras g12x mutant nsclc

Investigators Deliver Updates on Evolving Clinical Trials Evaluating ADCs in Lung Cancer

Melissa L. Johnson, MD, Terufumi Kato, MD, and Pasi A. Jänne, MD, PhD, present updates from the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer.

United statesDana farber cancer instituteIfinatamab deruxtecanMelissal johnsonTrastuzumab deruxtecanTerufumi katoHarvard medical schoolLowe centerChen huang centerSarah cannon research instituteCancer committee at tristar centennial medical centerBelfer centerInternational associationLung cancerCancer committeeTristar centennial medical center

Ifinatamab Deruxtecan Demonstrates Robust Efficacy, Acceptable Safety in SCLC

Melissa L. Johnson, MD, spotlights the early-phase investigation of ifinatamab deruxtecan in advanced solid tumors, discusses the efficacy and safety of the agent in patients with small cell lung cancer, and emphasizes how results from a subgroup analysis support its continued investigation.

United statesMelissal johnsonCommittee at tristar centennial medical centerOncology departmentLung cancer researchSarah cannon research instituteMedical executive committeeTristar centennial medical centerNext tsunamiIfinatamab deruxtecanPatients with heavily pretreated small cell lung cancer

Dr Johnson on the Initial Efficacy of Ifinatamab Deruxtecan in Refractory SCLC

Melissa L. Johnson, MD, discusses findings from a subgroup analysis of outcomes with ifinatamab deruxtecan in patients with refractory small cell lung cancer, which she presented at the 2023 IASLC World Conference on Lung Cancer.

Melissal johnsonOncology departmentLung cancer researchSarah cannon research instituteTristar centennial medical centerMedical executive committeePatients with small cell lung cancerInfinatamab deruxtecanI dxd ds 73002023 iaslc world conference on lung cancer

Dr Johnson on the Initial Efficacy of Infinatamab Deruxtecan in Refractory SCLC

Dr Johnson on the Initial Efficacy of Infinatamab Deruxtecan in Refractory SCLC
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Melissal johnsonTristar centennial medical centerLung cancer researchSarah cannon research instituteOncology departmentMedical executive committee